Format

Send to

Choose Destination
  • This is a preview / test site. Please update your PubMed URL to pubmed.gov.
See comment in PubMed Commons below
Atherosclerosis. 2010 Oct;212(2):512-5. doi: 10.1016/j.atherosclerosis.2010.06.041. Epub 2010 Jul 22.

Levels of asymmetrical dimethylarginine are predictive of brachial artery flow-mediated dilation 6 years later. The Cardiovascular Risk in Young Finns Study.

Author information

  • 1Division of Emergency, University Hospital of Tampere and University of Tampere Medical School, Tampere, Finland. hannu.paiva@pshp.fi

Abstract

AIM:

Plasma asymmetric dimethylarginine (ADMA) is a novel risk factor for atherosclerosis and has been observed to associate with endothelial function in cross-section studies. In the present study our aim was to investigate whether plasma ADMA levels are predictive of brachial artery endothelial function in a prospective setting.

METHODS AND RESULTS:

Using ultrasound we measured brachial artery flow-mediated dilation (FMD) both in 2001 and 2007 in 1808 healthy subjects aged 24-39 years at baseline. Plasma methylarginines were determined by isocratic high-pressure liquid chromatography in 2001. In a multivariable model adjusted with brachial diameter and conventional cardiovascular risk factors, baseline ADMA levels had a significant inverse association with FMD measured 6 years later (β±SE: -1.89±0.69%, P=0.006).

CONCLUSIONS:

We conclude that plasma ADMA can predict brachial artery FMD in subjects without prevalent atherosclerotic disease. These data suggest that plasma ADMA may have a determinative role in predicting endothelial function.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center